Teachers Retirement System of The State of Kentucky Purchases 13,019 Shares of Glaukos Co. (NYSE:GKOS)

Teachers Retirement System of The State of Kentucky increased its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 84.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 28,470 shares of the medical instruments supplier's stock after purchasing an additional 13,019 shares during the period. Teachers Retirement System of The State of Kentucky owned approximately 0.05% of Glaukos worth $3,709,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Glaukos by 6.0% during the third quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier's stock worth $152,722,000 after purchasing an additional 66,134 shares during the period. Barclays PLC lifted its holdings in Glaukos by 394.4% during the 3rd quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock worth $11,686,000 after buying an additional 71,556 shares during the period. EWA LLC acquired a new position in Glaukos during the 3rd quarter worth about $209,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Glaukos in the 3rd quarter valued at about $1,006,000. Finally, XTX Topco Ltd acquired a new stake in shares of Glaukos in the third quarter valued at about $404,000. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Down 1.0 %

NYSE GKOS traded down $1.39 on Friday, reaching $138.93. The company had a trading volume of 610,015 shares, compared to its average volume of 569,477. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $7.66 billion, a P/E ratio of -45.97 and a beta of 1.03. The company's fifty day moving average is $136.25 and its 200 day moving average is $126.81. Glaukos Co. has a 52-week low of $65.00 and a 52-week high of $147.65.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to analysts' expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business's revenue was up 23.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. Sell-side analysts anticipate that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Gilbert H. Kliman sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,656,707.36. This represents a 5.82 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company's stock, valued at $14,198,425.93. This represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on GKOS. Stifel Nicolaus lifted their price objective on Glaukos from $145.00 to $153.00 and gave the stock a "buy" rating in a research note on Monday, December 2nd. Stephens upgraded shares of Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com raised Glaukos from a "sell" rating to a "hold" rating in a research note on Monday, October 21st. Truist Financial raised their price objective on shares of Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $143.17.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.